<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25197967</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques.</ArticleTitle><Pagination><StartPage>e106756</StartPage><MedlinePgn>e106756</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e106756</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0106756</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) has caused epidemics of hand, foot and mouth diseases in Asia during the past decades and no vaccine is available. A formalin-inactivated EV71 candidate vaccine (EV71vac) based on B4 subgenotype has previously been developed and found to elicit strong neutralizing antibody responses in mice and humans. In this study, we evaluated the long-term immunogenicity and safety of this EV71vac in a non-human primate model. Juvenile macaques were immunized at 0, 3 and 6 weeks either with 10 or 5 &#xb5;g doses of EV71vac formulated with AlPO4 adjuvant, or PBS as control. During the 56 weeks of studies, no fever nor local redness and swelling at sites of injections was observed in the immunized macaques. After single immunization, 100% seroconversion based on 4-fold increased in neutralization titer (Nt) was detected in EV71vac immunized monkeys but not PBS controls. A dose-dependent IgG antibody response was observed in monkeys receiving EV71vac immunization. The Nt of EV71vac immunized macaques had reached the peak after 3 vaccinations, then decreased gradually; however, the GMT of neutralizing antibody in the EV71vac immunized macaques were still above 100 at the end of the study. Correspondingly, both dose- and time-dependent interferon-&#x3b3; and CD4+ T cell responses were detected in monkeys receiving EV71vac. Interestingly, similar to human responses, the dominant T cell epitopes of macaques were identified mainly in VP2 and VP3 regions. In addition, strong cross-neutralizing antibodies against most EV71 subgenotypes except some C2 and C4b strains, and Coxsackievirus A16 were observed. In summary, our results indicate that EV71vac elicits dose-dependent T-cell and antibody responses in macaques that could be a good animal model for evaluating the long-term immune responses elicited by EV71 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Chyi-Sing</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Animal Health Research Institute, Council of Agriculture, Tamsui, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wun-Syue</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Dan-Chin</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Sze-Hsien</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Ai-Hsiang</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Jen-Ron</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Centers for Disease Control, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chin-Cheng</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Animal Health Research Institute, Council of Agriculture, Tamsui, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chien-Hsiung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008251" MajorTopicYN="N">Macaca</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>To meet the requirement of PLOS ONE policy, the authors declare that Dr. C.C. Liu and Dr. P. Chong are named in U.S. patent application US20120045468 A1 for the development of EV71vac inactivated vaccine presented in this study. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials. All other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25197967</ArticleId><ArticleId IdType="pmc">PMC4157806</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0106756</ArticleId><ArticleId IdType="pii">PONE-D-14-18361</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC (2012) Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2: 199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashev AN, Lashkevich VA, Ivanova OE, Koroleva GA, Hinkkanen AE, et al. (2003) Recombination in circulating enteroviruses. J Virol 77: 10423&#x2013;10431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC228507</ArticleId><ArticleId IdType="pubmed">12970427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard K, Baltimore D (1986) The mechanism of RNA recombination in poliovirus. Cell 47: 433&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7133339</ArticleId><ArticleId IdType="pubmed">3021340</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90: 4171&#x2013;4175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46468</ArticleId><ArticleId IdType="pubmed">8387212</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, et al. (2013) Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One 8: e56341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SC, Hsu YW, Wang HC, Huang SW, Kiang D, et al. (2008) Appearance of intratypic recombination of enterovirus 71 in Taiwan from 2002 to 2005. Virus Res 131: 250&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">18036697</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoke-Fun C, AbuBakar S (2006) Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol 6: 74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569848</ArticleId><ArticleId IdType="pubmed">16939656</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, et al. (2010) EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 28: 3516&#x2013;3521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML (2011) The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol 37: 313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, et al. (2006) Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 60: 466&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, et al. (2009) Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol 83: 6477&#x2013;6483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698549</ArticleId><ArticleId IdType="pubmed">19386699</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, et al. (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109: e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, et al. (2004) Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 291: 222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722149</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386&#x2013;9395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, et al. (2008) Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26: 2882&#x2013;2889.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, et al. (2006) Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12: 921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, et al. (2012) Production of EV71 vaccine candidates. Hum Vaccin Immunother 8: 1775&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30: 3295&#x2013;3303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, et al. (2013) A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31: 2471&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, et al. (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381: 2024&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, et al. (2013) Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. PLoS One 8: e79783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, et al. (2012) Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 7: e34834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328501</ArticleId><ArticleId IdType="pubmed">22529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Wang J, Liu L, Zhao H, Shi H, et al. (2010) Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 6: 1028&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">21150270</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29: 6269&#x2013;6275.</Citation><ArticleIdList><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, et al. (2012) Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30: 1305&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, et al. (2013) A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol 158: 1523&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">23456422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, Tan X, Sun X, Lu G, Chen CC, et al. (2013) VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population. J Immunol 191: 1637&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863902</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen FH, Tsai CC, Wang LC, Chang KC, Tung YY, et al. (2013) Enterovirus 71 infection increases expression of interferon-gamma-inducible protein 10 which protects mice by reducing viral burden in multiple tissues. J Gen Virol 94: 1019&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">23288420</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Partidos CD, Santangelo JD, Osorio JE (2013) Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS One 8: e59501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602422</ArticleId><ArticleId IdType="pubmed">23527208</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel K, Schnorr JJ, Sauter M, Szalay G, Kandolf R (2003) beta2-microglobulin-associated regulation of interferon-gamma and virus-specific immunoglobulin G confer resistance against the development of chronic coxsackievirus myocarditis. Am J Pathol 162: 1709&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851178</ArticleId><ArticleId IdType="pubmed">12707055</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CS, Cardosa MJ (2007) High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol 152: 1069&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">17318736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutubuddin M, Simons J, Chow M (1992) Identification of T-helper epitopes in the VP1 capsid protein of poliovirus. J Virol 66: 3042&#x2013;3047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241064</ArticleId><ArticleId IdType="pubmed">1373200</ArticleId></ArticleIdList></Reference><Reference><Citation>Cello J, Strannegard O, Svennerholm B (1996) A study of the cellular immune response to enteroviruses in humans: identification of cross-reactive T cell epitopes on the structural proteins of enteroviruses. J Gen Virol 77 (Pt 9): 2097&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811009</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 47: 3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>